^
Association details:
| Biomarker: | FIP1L1-PDGFRA rearrangement |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Imatinib therapy in acute myeloid leukemia with DEK-NUP214 and FIP1L1-PDGFRA rearrangement: A case report
Published date:
03/10/2020
Excerpt:
...the present study reported that monotherapy with imatinib induced hematological remission even in a rare case of AML associated with DEK-NUP214 and FIP1L1-PDGFRA rearrangements when leukemia relapsed. During hematological remission, the patient was in good compliance with imatinib without side effects. The present case study indicated that the tyrosine kinase inhibitor may be a sensitive and effective treatment for patients with AML with FIP1L1-PDGFRA rearrangement.
DOI:
10.3892/ol.2020.11455
